Table 7.

Patents protecting selected toxins

Technology	Example IP right	Assignee	Claim language
Auristatins (MMAE, MMAF)	US6884869	Seattle Genetics	A compound of the formula and pharmaceutically acceptable salts and solvates there of wherein […]
Maytansinoids plus SMCC linker	US5208020*	ImmunoGen	A cytotoxic agent comprising one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, −14, −15, or −20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens.
New anthracyclin derivatives	US8900589	Genentech	An antibody-drug conjugate compound comprising an antibody covalently attached by a linker L and an optional spacer Z to one or more anthracycline derivative drug moieties D, the compound having the formula (D-L-(Z)m)p-Ab or a pharmaceutically acceptable salt thereof, wherein: Ab is an antibody;
			D is an anthracycline derivative selected from the structures A and B: […]
Calicheamicins	US5714586	American Cyanamid Company	A method for preparing monomeric calicheamicin derivative/carrier conjugates with higher drug loading/yield and decreased aggregation having the formula, Pr(–X–S–S–W)m wherein: Pr is a proteinaceous carrier, X is a linker that comprises a product of any reactive group that can react with a proteinaceous carrier, W is the calicheamicin radical formed by removal of the naturally occurring methyl trisulfide group […]
Duocarmycins	EP2560645A2	Syntarga	1. A compound of formula (III): wherein […] each Z is independently a compound of formula (I), (II), (I'), or (IΓ): […]
Novel taxanes	US7390898	ImmunoGen	A compound represented by formula (I): wherein […]
Pyrrolobenzodiazepine	EP2766048B1	ADC Therapeutic & Spirogen Limited	A conjugate of formula ConjB:: where CBA represents a cell binding agent.
α-amanitin	EP2436398B1	Heidelberg Pharma	A conjugate comprising a target-binding moiety linked via a linker L to an amatoxin, wherein the linker L is connected to the amatoxin via(i) the γ C-atom of amatoxin amino acid 1, particularly via an amide linkage;(ii) an oxygen atom bound to the δ C-atom of amatoxin amino acid 3, particularly via an ester linkage, an ether linkage or a urethane linkage; or(iii) the 6′ C-atom of amatoxin amino acid 4, particularly via an oxygen atom bound to the 6′ C-atom of amatoxin amino acid 4; in each case wherein the linker L is connected to the target-binding moiety via a urea moiety.
CC-1065 (duocarmycin)	US5475092* US5585499*	ImmunoGen	A cytotoxic agent comprising a cell binding agent linked via a disulfide bond to one or more analogs or derivatives of a cyclopropylbenzindole-containing cytotoxic drug, wherein said cell binding agent is a monoclonal antibody or an antigen-binding fragment of a monoclonal antibody having at least one binding site thereof, and wherein prior to linking said analogs or derivatives to said cell binding agent said analogs or derivatives are selected from the group consisting of analogs or derivatives formed from an A subunit of the formulae (A-3) or (A-4) and a B-C subunit of the formulae (F-3), (F-4), (F-5) or (F-6), said B-C subunit having a B moiety shown on the left-hand side of the formulae and a C moiety shown on the right-hand side of the formulae and wherein said A subunit is covalently linked to said B-C subunit via an amide bond from the secondary amino group of the pyrrole moiety of the A subunit to the C-2 carboxyl group of the B moiety of the B-C subunit, wherein the formulae (A-3) and (A-4) are as follows […] wherein the formulae (F-3) to (F-6) are as follows: […]
De-immunized bouganin protein toxin	US8716234	Merck	A method of inhibiting or destroying a lymphoma cancer cell comprising administering a cytotoxin to an animal having lymphoma, wherein said cytotoxin comprises a targeting moiety that binds to the lymphoma cancer cell and is linked to a modified bouganin protein, wherein said modified bouganin protein comprises AA sequence SEQ ID NO: 11, […]
Tubulysins	US2015141646	Concortis	1. A compound having the structure of Formula I: or a pharmaceutically acceptable salt thereof, wherein: A is a tubulin binding moiety; B is a functional moiety; […]
Benzodiazepine derivatives	US8765740	ImmunoGen	1. A compound represented by the following formula: or a pharmaceutically acceptable salt thereof, wherein: the double line – between N and C represents a single bond or a double bond, […]
Pyrrolobenzodiazepine	US2013028919	Seattle/Spirogen	A Conjugate having formula L-(LU-D)p or a pharmaceutically acceptable salt or solvate thereof; wherein L is a Ligand unit, LU is a Linker unit, p is 1 to 20; and D is a Drug unit comprising a PBD dimer having the following formula II wherein: R2 is 2'X […]
Pyrrolobenzodiazepines	US20110256157	Spirogen	A conjugate of formula (A) and salts and solvates thereof, wherein: the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; […] or the compound is a dimer with each monomer being of formula (A), or with one monomer being of formula (A) and the other being of formula (B): wherein […]

^*expired; the symbol […] indicates that claim language has been truncated.